The Top 5 Biosimilar Articles for the Week of July 26

Video

Here are the top 5 biosimilar articles for the week of July 26, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of July 26, 2021.

Number 5: Biosimilar uptake could be more robust in the United States if the FDA can be convinced that biosimilars are worth the effort, said Rep Kurt Schrader, D-Oregon.

Number 4: Shanghai Henlius Biotech initiated a trial for patients with macular degeneration while Dong-A ST and Meiji Seika Pharma agreed on a distribution plan for a ustekinumab biosimilar candidate.

Number 3: Biocon reported on its revenues from biosimilars and the FDA status of its insulin glargine product.

Number 2: The Biologics Price Competition and Innovation Act (BPCIA) provides a stepwise approach for fact-finding prior to patent litigation, but companies may choose their own path, case examples showed.

Number 1: Without disclosing terms, Pfizer said it settled with Johnson & Johnson (J&J) over a long-running dispute in which J&J was alleged to have blocked payers from covering Inflectra.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Legal scale weighs profit as greater than medical treatment
Here are the top 5 biosimilar articles for the week of March 18, 2024.
Here are the top 5 biosimilar articles for the week of March 11, 2024.
Ha Kung Wong, JD
Here are the top 5 biosimilar articles for the week of March 4, 2024.
The Top 5 Biosimilar Articles for the Week of February 26
Ha Kung Wong, JD.
The Top 5 Biosimilar Articles for the Week of February 19, 2024.
Here are the top 5 biosimilar articles for the week of February 12, 2024.
Ha Kung Wong, JD
Related Content
© 2024 MJH Life Sciences

All rights reserved.